These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

158 related articles for article (PubMed ID: 36814265)

  • 1. Clinical outcomes and lung toxicities after lung SABR using dynamic conformal arc therapy: a single-institution cohort study.
    Mesny E; Ayadi M; Dupuis P; Beldjoudi G; Tanguy R; Martel-Lafay I
    Radiat Oncol; 2023 Feb; 18(1):36. PubMed ID: 36814265
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Clinical and dosimetric predictors of radiation pneumonitis in early-stage lung cancer treated with Stereotactic Ablative radiotherapy (SABR) - An analysis of UK's largest cohort of lung SABR patients.
    Saha A; Beasley M; Hatton N; Dickinson P; Franks K; Clarke K; Jain P; Teo M; Murray P; Lilley J
    Radiother Oncol; 2021 Mar; 156():153-159. PubMed ID: 33333139
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Planning Target Volume D95 and Mean Dose Should Be Considered for Optimal Local Control for Stereotactic Ablative Radiation Therapy.
    Zhao L; Zhou S; Balter P; Shen C; Gomez DR; Welsh JD; Lin SH; Chang JY
    Int J Radiat Oncol Biol Phys; 2016 Jul; 95(4):1226-35. PubMed ID: 27209498
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pre-treatment non-target lung FDG-PET uptake predicts symptomatic radiation pneumonitis following Stereotactic Ablative Radiotherapy (SABR).
    Chaudhuri AA; Binkley MS; Rigdon J; Carter JN; Aggarwal S; Dudley SA; Qian Y; Kumar KA; Hara WY; Gensheimer M; Nair VS; Maxim PG; Shultz DB; Bush K; Trakul N; Le QT; Diehn M; Loo BW; Guo HH
    Radiother Oncol; 2016 Jun; 119(3):454-60. PubMed ID: 27267049
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Optimizing SABR delivery for synchronous multiple lung tumors using volumetric-modulated arc therapy.
    Tekatli H; Tetar SU; Nguyen TK; Warner A; Verbakel WF; Palma DA; Dahele M; Gaede S; Haasbeek C; Spoelstra FO; de Haan PF; Slotman BJ; Senan S
    Acta Oncol; 2017 Apr; 56(4):548-554. PubMed ID: 28358667
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Predictive factors for local control in primary and metastatic lung tumours after four to five fraction stereotactic ablative body radiotherapy: a single institution's comprehensive experience.
    Thibault I; Poon I; Yeung L; Erler D; Kim A; Keller B; Lochray F; Jain S; Soliman H; Cheung P
    Clin Oncol (R Coll Radiol); 2014 Nov; 26(11):713-9. PubMed ID: 25085765
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Feasibility study of stereotactic body radiotherapy for peripheral lung tumors with a maximum dose of 100 Gy in five fractions and a heterogeneous dose distribution in the planning target volume.
    Takeda A; Oku Y; Sanuki N; Eriguchi T; Aoki Y; Enomoto T; Kaneko T; Nishimura S; Kunieda E
    J Radiat Res; 2014 Sep; 55(5):988-95. PubMed ID: 24833770
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Predicting radiation pneumonitis after stereotactic ablative radiation therapy in patients previously treated with conventional thoracic radiation therapy.
    Liu H; Zhang X; Vinogradskiy YY; Swisher SG; Komaki R; Chang JY
    Int J Radiat Oncol Biol Phys; 2012 Nov; 84(4):1017-23. PubMed ID: 22543216
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Dosimetric benefits of dynamic conformal arc therapy-combined with active breath-hold in lung stereotactic body radiotherapy.
    Lee S; Lee D; Verma V; Waters D; Oh S; Colonias A; Wegner R; Pavord D; Coopey B; Fuhrer R; Sohn JW
    Med Dosim; 2022 Spring; 47(1):54-60. PubMed ID: 34583857
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A dosimetric comparison of three-dimensional conformal radiotherapy, volumetric-modulated arc therapy, and dynamic conformal arc therapy in the treatment of non-small cell lung cancer using stereotactic body radiotherapy.
    Rauschenbach BM; Mackowiak L; Malhotra HK
    J Appl Clin Med Phys; 2014 Sep; 15(5):4898. PubMed ID: 25207575
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A dosimetric comparison between volumetric-modulated arc therapy and dynamic conformal arc therapy in SBRT.
    Stathakis S; Narayanasamy G; Licon AL; Myers P; Li Y; Crownover R; Papanikolaou N
    J BUON; 2019; 24(2):838-843. PubMed ID: 31128044
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Safety and Efficacy of Stereotactic Ablative Radiation Therapy for Renal Cell Carcinoma Extracranial Metastases.
    Wang CJ; Christie A; Lin MH; Jung M; Weix D; Huelsmann L; Kuhn K; Meyer J; Desai N; Kim DWN; Pedrosa I; Margulis V; Cadeddu J; Sagalowsky A; Gahan J; Laine A; Xie XJ; Choy H; Brugarolas J; Timmerman R; Hannan R
    Int J Radiat Oncol Biol Phys; 2017 May; 98(1):91-100. PubMed ID: 28587057
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Stereotactic ablative radiotherapy (SABR) for treatment of central and ultra-central lung tumors.
    Chaudhuri AA; Tang C; Binkley MS; Jin M; Wynne JF; von Eyben R; Hara WY; Trakul N; Loo BW; Diehn M
    Lung Cancer; 2015 Jul; 89(1):50-6. PubMed ID: 25997421
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Stereotactic ablative body radiation therapy with dynamic conformal multiple arc therapy for liver tumors: optimal isodose line fitting to the planning target volume.
    Oku Y; Takeda A; Sanuki N; Sudo Y; Oooka Y; Aoki Y; Shimouchi Y; Nishina R; Nomura K; Eriguchi T; Kunieda E
    Pract Radiat Oncol; 2014; 4(1):e7-e13. PubMed ID: 24621435
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Local control and toxicity after magnetic resonance imaging (MR)-guided single fraction lung stereotactic ablative radiotherapy.
    Tekatli H; Palacios MA; Schneiders FL; Haasbeek CJA; Slotman BJ; Lagerwaard FJ; Senan S
    Radiother Oncol; 2023 Oct; 187():109823. PubMed ID: 37516364
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Hypofractionated image-guided breath-hold SABR (stereotactic ablative body radiotherapy) of liver metastases--clinical results.
    Boda-Heggemann J; Dinter D; Weiss C; Frauenfeld A; Siebenlist K; Attenberger U; Ottstadt M; Schneider F; Hofheinz RD; Wenz F; Lohr F
    Radiat Oncol; 2012 Jun; 7():92. PubMed ID: 22710033
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Can dosimetry affect local control and survival in patients with early-stage lung cancer treated with Stereotactic Ablative Radiotherapy (SABR)? An analysis of the UK's largest cohort of lung SABR patients.
    Saha A; Beasley M; Hatton N; Dickinson P; Franks K; Clarke K; Jain P; Teo M; Murray P; Lilley J
    Acta Oncol; 2021 Apr; 60(4):505-512. PubMed ID: 33491521
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Dosimetric comparison of helical tomotherapy and dynamic conformal arc therapy in stereotactic radiosurgery for vestibular schwannomas.
    Lee TF; Chao PJ; Wang CY; Lan JH; Huang YJ; Hsu HC; Sung CC; Su TJ; Lian SL; Fang FM
    Med Dosim; 2011; 36(1):62-70. PubMed ID: 20188537
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Stereotactic ablative radiation therapy for centrally located early stage or isolated parenchymal recurrences of non-small cell lung cancer: how to fly in a "no fly zone".
    Chang JY; Li QQ; Xu QY; Allen PK; Rebueno N; Gomez DR; Balter P; Komaki R; Mehran R; Swisher SG; Roth JA
    Int J Radiat Oncol Biol Phys; 2014 Apr; 88(5):1120-8. PubMed ID: 24661665
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Treating lung cancer with dynamic conformal arc therapy: a dosimetric study.
    Peterlin P; Stanič K; Méndez I; Strojnik A
    Radiat Oncol; 2017 Jun; 12(1):93. PubMed ID: 28578699
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.